Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Gynecol Oncol ; 83(2): 216-20, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11606074

ABSTRACT

OBJECTIVE: The objective of this study was to determine whether clinicopathologic findings or the immunohistochemical presence of molecular markers are predictive of clinical outcome in patients with small cell carcinoma of the cervix (SCCC). METHODS: A retrospective review of cases of carcinoma of the cervix was conducted to identify SCCC. From 1978 to 1999, 16 patients were identified at our institution with the diagnosis of SCCC. Microscopic sections of paraffin-embedded tissue specimens were evaluated for confirmation of diagnosis. Specimens were immunohistochemically stained with antibodies to three neuroendocrine markers: neuron-specific enolase, chromagranin (CGR), and synaptophysin. Specimens were also stained for protein expression of p53, erbB2, proliferating cell nuclear antigen, and c-myc. The relationship between molecular markers and clinical outcome was determined. RESULTS: All 16 cases met the histologic criteria for SCCC. Fourteen of 16 tumors (88%) stained positive for neuroendocrine differentiation. Eleven of 16 patients (69%) died from disease with a median survival of 19 months; there were 3 long-term survivors (greater than 5 years). CGR was positive in 8 (50%) specimens and was found to be highly predictive of death (P = 0.001). Complete loss of p53 protein was seen in 8 patients, 7 of whom died with a median survival of 20 months. CONCLUSION: Immunohistochemistry can be helpful in confirming difficult cases of SCCC. Further studies are necessary to define molecular markers that may be predictive of outcome in patients with SCCC.


Subject(s)
Carcinoma, Small Cell/metabolism , Carcinoma, Small Cell/pathology , Uterine Cervical Neoplasms/metabolism , Uterine Cervical Neoplasms/pathology , Adult , Biomarkers, Tumor/biosynthesis , Biomarkers, Tumor/genetics , Chromogranins/metabolism , Female , Humans , Immunohistochemistry , Middle Aged , Neoplasm Staging , Phosphopyruvate Hydratase/metabolism , Predictive Value of Tests , Prognosis , Proliferating Cell Nuclear Antigen/biosynthesis , Proliferating Cell Nuclear Antigen/genetics , Proto-Oncogene Proteins c-myc/biosynthesis , Proto-Oncogene Proteins c-myc/genetics , Receptor, ErbB-2/biosynthesis , Receptor, ErbB-2/genetics , Retrospective Studies , Synaptophysin/metabolism , Tumor Suppressor Protein p53/biosynthesis , Tumor Suppressor Protein p53/genetics
3.
South Med J ; 94(7): 744-6, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11531187

ABSTRACT

A 43-year-old woman who had a vulvar mass associated with mild discomfort was found to have a rare primary vulvar adenocarcinoma of probable cloacal origin. The tumor was contiguous with the surface epithelium of the vulva and was a well to moderately differentiated adenocarcinoma of colonic type. Stains of the neoplastic cells were positive for both acid and neutral mucin, and periodic acid-Schiff (PAS) was positive after diastase reaction. The neoplastic cells were strongly positive for carcinoembryonic antigen, broad spectrum cytokeratin, and p-53 antigen. Clinical evaluation failed to show any primary tumor in colon, lung, or breast. The patient was disease free 18 months after operation.


Subject(s)
Adenocarcinoma/pathology , Cloaca , Vulvar Neoplasms/pathology , Adenocarcinoma/etiology , Adenocarcinoma/surgery , Adult , Female , Humans , Vulvar Neoplasms/etiology , Vulvar Neoplasms/surgery
4.
Ann Surg ; 233(5): 630-8, 2001 May.
Article in English | MEDLINE | ID: mdl-11323501

ABSTRACT

OBJECTIVE: To assess the prognostic significance of molecular biomarkers, particularly c-erbB-2 and p53, through study of prospective clinical data and archival breast cancer tissues for women accrued to the Alabama Breast Cancer Project. SUMMARY BACKGROUND DATA: Defining molecular abnormalities in breast cancer is an important strategy for early detection, assessment of prognosis, and treatment selection. Evidence is strong that selective biomarkers, including c-erbB-2 and p53, have prognostic significance in breast cancer. Few studies have analyzed the prognostic significance of coexpression of biomarkers. METHODS: Study patients were those accrued to the Alabama Breast Cancer Project (1975-1978) who had archival breast cancer tissues available for analysis. Criteria for entrance into the Alabama Breast Cancer Project were T1-3 breast cancer with M0 status. Age, nodal status, and histologic grade were also documented. Patients were randomized to radical versus modified radical mastectomy, and node-positive patients were also randomized to adjuvant chemotherapy (cyclophosphamide, methotrexate, and 5-fluorouracil [CMF]) versus melphalan. Archival breast cancer tissues were studied for c-erbB-2, TGF-alpha, p53, cathepsin D, bcl-2, and estrogen and progesterone receptor expression using immunohistochemistry. Survival curves were developed using the Kaplan-Meier method. Univariate analysis was performed using the log-rank test, multivariate analysis using a rank regression model. RESULTS: Three hundred eleven patients were accrued to the Alabama Breast Cancer Project, and paraffin-embedded breast cancer tissues for 90 patients were available for immunohistochemical analysis of molecular biomarkers. Univariate analysis showed nodal status, c-erbB-2 expression, and p53 expression to have prognostic significance. Coexpression of c-erbB-2 and p53 was also found to have prognostic significance by the log-rank test. Multivariate analysis showed T stage, nodal status, c-erbB-2 expression, and p53 expression to have independent prognostic significance. CONCLUSIONS: These data suggest that c-erbB-2 and p53 expression in breast cancer have prognostic significance. After median follow-up of 16 years, coexpression of c-erbB-2 and p53 may have more prognostic significance than traditional prognostic factors such as T stage and nodal status. Prospective study of large numbers of patients with breast cancer is encouraged to validate these findings.


Subject(s)
Biomarkers, Tumor , Breast Neoplasms/genetics , Receptor, ErbB-2/metabolism , Tumor Suppressor Protein p53/metabolism , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/mortality , Breast Neoplasms/surgery , Chemotherapy, Adjuvant , Female , Humans , Immunohistochemistry , Mastectomy, Radical , Middle Aged , Prognosis , Prospective Studies , Randomized Controlled Trials as Topic
5.
South Med J ; 93(2): 226-8, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10701796

ABSTRACT

Choriocarcinoma has been reported in association with endometrial carcinoma and as a metaplastic change in multiple carcinomas, including liver, urinary bladder, lung, and the gastrointestinal tract. We report choriocarcinoma in conjunction with a carcinosarcoma (also called malignant müllerian mixed tumor) in a 71-year-old woman whose hysterectomy specimen revealed two polypoid lesions of the endometrium, one arising from the anterior endometrium and one arising from the posterior endometrium. Histologic examination revealed three histologic patterns. The anterior endometrial lesion showed a FIGO grade 2 endometrioid endometrial adenocarcinoma. The posterior endometrial lesion showed a carcinosarcoma composed of a high-grade adenocarcinoma and scant homologous stromal sarcoma. In addition, a choriocarcinoma was identified intermixed with the adenocarcinoma. The syncytiocytotrophoblasts and cytotrophoblasts stained strongly with 0 human chorionic gonadotropin (beta-hCG) and human placental lactogen (hPL). The patient's beta-hCG levels on postoperative days 14, 27, and 42 were 283, 32, and 7 mIU/mL, respectively. This unusual case suggests the importance of identifying the choriocarcinomatous component, since the serum beta-hCG can serve as a marker of tumor recurrence postoperatively.


Subject(s)
Carcinoma, Endometrioid/pathology , Carcinosarcoma/pathology , Choriocarcinoma/complications , Choriocarcinoma/pathology , Endometrial Neoplasms/pathology , Mixed Tumor, Mullerian/pathology , Ovarian Neoplasms/pathology , Uterine Neoplasms/complications , Uterine Neoplasms/pathology , Aged , Biomarkers, Tumor/isolation & purification , Carcinoma, Endometrioid/complications , Carcinosarcoma/complications , Choriocarcinoma/surgery , Chorionic Gonadotropin, beta Subunit, Human/blood , Endometrial Neoplasms/complications , Female , Humans , Hysterectomy , Mixed Tumor, Mullerian/complications , Ovarian Neoplasms/complications , Treatment Outcome , Uterine Neoplasms/surgery
6.
Ann Diagn Pathol ; 3(1): 23-34, 1999 Feb.
Article in English | MEDLINE | ID: mdl-9990110

ABSTRACT

Twenty-four years after apparently successful treatment for nodular lymphocyte predominant Hodgkin's disease (nLPHD), a 41-year old male developed "B" symptoms and extensive adenopathy. A right axillary lymph node biopsy showed two distinct regions including (1) histiocyte-rich B-cell lymphoma and (2) diffuse small T-cell lymphoma. A clonal rearrangement of the gene for the T-cell receptor beta chain confirmed the presence of a T-cell neoplasm, and this was further confirmed by selective polymerase chain reaction (PCR) on this morphologic zone. PCR on the morphologic B-cell lymphoma confirmed the presence of an immunoglobulin gene rearrangement. These two regions were separated by a less-defined zone containing a mixture of small CD57 positive T lymphocytes, small B lymphocytes, and rare lymphocytic and histiocytic (L&H) cells, highly suggestive of recurrent LPHD. The development of composite B-cell and T-cell lymphoma in this patient raises the speculation that nLPHD may be a neoplasm of lymphoid cells, which can differentiate in both B- and T-cell directions, with the "L&H" cells constituting their B-cell progeny.


Subject(s)
Hodgkin Disease/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma, B-Cell/pathology , Lymphoma, Non-Hodgkin/pathology , Lymphoma, T-Cell/pathology , Adolescent , Adult , Biopsy , Flow Cytometry , Fluorescent Antibody Technique, Indirect , Gene Rearrangement, B-Lymphocyte, Heavy Chain/genetics , Gene Rearrangement, beta-Chain T-Cell Antigen Receptor/genetics , Hodgkin Disease/genetics , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Lymph Nodes/pathology , Lymphoma, B-Cell/genetics , Lymphoma, Non-Hodgkin/genetics , Lymphoma, T-Cell/genetics , Male , Polymerase Chain Reaction , Reed-Sternberg Cells/pathology
7.
Psychol Rep ; 79(3 Pt 2): 1395-422, 1996 Dec.
Article in English | MEDLINE | ID: mdl-9009798

ABSTRACT

Managed mental health care cost-containment practices of risk-benefit analysis, provider usage, manipulation of supply and demand, gate keeping, medical necessity, and formulation have adversely affected quality of care. Improved mental health services are dependent upon redefining mental health problems and understanding inequities created by medicalization as means to limit access to services. This dilemma can be addressed by development of mental health policy, public education, and political advocacy. An immediate role for professional psychology is found in the creation of a research agenda that documents empirically supported interventions for specific mental health problems, mechanisms of effective and acceptable service-delivery, and identification of providers with demonstrated clinical skills, including cultural competencies.


Subject(s)
Health Policy/economics , Managed Care Programs/economics , Mental Health Services/economics , Patient Advocacy , Quality Assurance, Health Care/economics , Cost Control/trends , Forecasting , Health Services Accessibility/economics , Humans , Politics , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...